REGENERON PHARMACEUTICALS, INC.

Lobbying client · New York · filed 2025 to 2026

Biopharmaceutical development and manufacturing

$50,000 Reported spend

6 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 6 filings. Everything on this page is grouped by the client's LDA id (210738), not by name.

Firms hired 1

ARNOLD & PORTER KAYE SCHOLER LLP $50,000 6 filings

Reported by year 2 years

2026 $50,000 2 filings
2025 $0 4 filings

Issues lobbied 2

Health Issues 2
Budget/Appropriations 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

SENATE 2
HOUSE OF REPRESENTATIVES 1

Recent filings 6 total

Q2

ARNOLD & PORTER KAYE SCHOLER LLP

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000 income · posted Jul 20, 2026

View → Q1

ARNOLD & PORTER KAYE SCHOLER LLP

1st Quarter (Jan 1 - Mar 31) 2026 · Senate · posted Apr 20, 2026

View → Q4Y

ARNOLD & PORTER KAYE SCHOLER LLP

4th Quarter (Oct 1 - Dec 31) 2025 · posted Jan 16, 2026

View → Q3Y

ARNOLD & PORTER KAYE SCHOLER LLP

3rd Quarter (July 1 - Sep 30) 2025 · posted Oct 16, 2025

View → Q2Y

ARNOLD & PORTER KAYE SCHOLER LLP

2nd Quarter (Apr 1 - June 30) 2025 · posted Jul 17, 2025

View → Q1Y

ARNOLD & PORTER KAYE SCHOLER LLP

1st Quarter (Jan 1 - Mar 31) 2025 · posted Apr 21, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.